Ngā hua rapu kaituhi

1

Management of direct antiviral agent failures mā Marı́a Buti, Rafael Esteban

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
2

Natural History and Management of Hepatitis C: Does Sex Play a Role? mā Rachel Baden, Jürgen K. Rockstroh, Marı́a Buti

I whakaputaina 2014

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

Long‐term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B mā Marı́a Buti, Mar Riveiro‐Barciela, Rafael Esteban

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
4

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B mā Luisa Roade, Mar Riveiro‐Barciela, Rafael Esteban, Marı́a Buti

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
5

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients mā Markus Cornberg, Marı́a Buti, Christiane S. Eberhardt, Paolo Grossi, Daniel Shouval

I whakaputaina 2021

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
6

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoint... mā Marc G. Ghany, Marı́a Buti, Pietro Lampertico, Hannah M. Lee

I whakaputaina 2023

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

Genetic analysis of hepatitis A virus strains recovered from the environment and from patients with acute hepatitis mā Sonia Pina-Pedrero, Marı́a Buti, R Jardí, Pilar Clemente-Casares, Joan Jofre, Rosina Gironés

I whakaputaina 2001

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Hepatitis B virus infection: Precore mutants and its relation to viral genotypes and core mutations mā Francisco Rodríguez‐Frías, Marı́a Buti, Rosendo Jardí, Montserrat Cotrina, L Viladomiu, Rafael Esteban, Jaime Guardia

I whakaputaina 1995

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020) mā Manuel Rodríguez, Marı́a Buti, Rafael Esteban, Sabela Lens, M. Prieto, Emilio Suárez, Javier García‐Samaniego

I whakaputaina 2020

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative inte... mā Rosendo Jardí, F. Rodrı́guez, Marı́a Buti, X. Costa, Montserrat Cotrina, R. Galimany, Rafael Esteban, Jaime Guardia

I whakaputaina 2001

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin mā Marı́a Buti, J.F. Sánchez-Ávila, Yoav Lurie, Carlos Stalgis, Auristela Valdés, M. Martell, Rafael Esteban

I whakaputaina 2002

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey mā Loreta A. Kondili, Marı́a Buti, Mar Riveiro‐Barciela, Mojca Matičič, Francesco Negro, Thomas Berg, Antonio Craxı̀

I whakaputaina 2022

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

Hepatitis E Virus Epidemiology in Industrialized Countries mā Pilar Clemente-Casares, Sonia Pina-Pedrero, Marı́a Buti, R Jardí, Marga Martı́n, Sílvia Bofill-Mas, Rosina Gironés

I whakaputaina 2003

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Direct‐acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study mā A. Singer, K. Rajender Reddy, Laura Telep, Anu Osinusi, Diana M. Brainard, Marı́a Buti, Anand P. Chokkalingam

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? mā Mar Riveiro‐Barciela, Eva Muñoz‐Couselo, Jesús Fernández‐Sojo, Nely Díaz‐Mejía, Rafael Parra-López, Marı́a Buti

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Carta

Tiaki ki tētahi rārangi

I tiakina i:
16

Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study mā Marı́a Buti, María Homs, Francisco Rodríguez‐Frías, G. Funalleras, Rosendo Jardí, Sílvia Sauleda, David Tabernero, M. Schaper, Rafael Esteban

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

Adherence to Lamivudine After an Early Withdrawal of Hepatitis B Immune Globulin Plays an Important Role in the Long-Term Prevention of Hepatitis B Virus Recurrence mā Marı́a Buti, Antoni Mas, M. Prieto, Fernando Casafont, Antonio González, Manuel Miras, J.I. Herrero, Rosendo Jardí, Rafael Esteban

I whakaputaina 2007

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D mā Marı́a Buti, José Luís Calleja, Miguel Ángel Rodríguez, Raquel Domínguez‐Hernández, Helena Cantero, Nataly Espinoza-Cámac, Miguel Á. Casado

I whakaputaina 2025

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with he... mā Nicolaos C. Tassopoulos, Riccardo Volpes, Giuseppe Pastore, Jenny Heathcote, Marı́a Buti, Robert Goldin, Sasha Hawley, Judy Barber, Lynn D. Condreay, Fraser Gray

I whakaputaina 1999

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

Community-Based Seroepidemiological Survey of Hepatitis E Virus Infection in Catalonia, Spain mā Marı́a Buti, Ángela Domı́nguez, Pere Plans, Rossend Jardí, M. Schaper, Jordi Espuñes, Neus Cardeñosa, Francisco Rodríguez‐Frías, Rafael Esteban, Antoni Plasència, L. Salleras

I whakaputaina 2006

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Maria Buti

Management of direct antiviral agent failures mā Marı́a Buti, Rafael Esteban

Natural History and Management of Hepatitis C: Does Sex Play a Role? mā Rachel Baden, Jürgen K. Rockstroh, Marı́a Buti

Long‐term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B mā Marı́a Buti, Mar Riveiro‐Barciela, Rafael Esteban

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B mā Luisa Roade, Mar Riveiro‐Barciela, Rafael Esteban, Marı́a Buti

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients mā Markus Cornberg, Marı́a Buti, Christiane S. Eberhardt, Paolo Grossi, Daniel Shouval

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoint... mā Marc G. Ghany, Marı́a Buti, Pietro Lampertico, Hannah M. Lee

Genetic analysis of hepatitis A virus strains recovered from the environment and from patients with acute hepatitis mā Sonia Pina-Pedrero, Marı́a Buti, R Jardí, Pilar Clemente-Casares, Joan Jofre, Rosina Gironés

Hepatitis B virus infection: Precore mutants and its relation to viral genotypes and core mutations mā Francisco Rodríguez‐Frías, Marı́a Buti, Rosendo Jardí, Montserrat Cotrina, L Viladomiu, Rafael Esteban, Jaime Guardia

Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020) mā Manuel Rodríguez, Marı́a Buti, Rafael Esteban, Sabela Lens, M. Prieto, Emilio Suárez, Javier García‐Samaniego

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin mā Marı́a Buti, J.F. Sánchez-Ávila, Yoav Lurie, Carlos Stalgis, Auristela Valdés, M. Martell, Rafael Esteban

Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey mā Loreta A. Kondili, Marı́a Buti, Mar Riveiro‐Barciela, Mojca Matičič, Francesco Negro, Thomas Berg, Antonio Craxı̀

Hepatitis E Virus Epidemiology in Industrialized Countries mā Pilar Clemente-Casares, Sonia Pina-Pedrero, Marı́a Buti, R Jardí, Marga Martı́n, Sílvia Bofill-Mas, Rosina Gironés

Direct‐acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study mā A. Singer, K. Rajender Reddy, Laura Telep, Anu Osinusi, Diana M. Brainard, Marı́a Buti, Anand P. Chokkalingam

Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? mā Mar Riveiro‐Barciela, Eva Muñoz‐Couselo, Jesús Fernández‐Sojo, Nely Díaz‐Mejía, Rafael Parra-López, Marı́a Buti

Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study mā Marı́a Buti, María Homs, Francisco Rodríguez‐Frías, G. Funalleras, Rosendo Jardí, Sílvia Sauleda, David Tabernero, M. Schaper, Rafael Esteban

Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D mā Marı́a Buti, José Luís Calleja, Miguel Ángel Rodríguez, Raquel Domínguez‐Hernández, Helena Cantero, Nataly Espinoza-Cámac, Miguel Á. Casado

Community-Based Seroepidemiological Survey of Hepatitis E Virus Infection in Catalonia, Spain mā Marı́a Buti, Ángela Domı́nguez, Pere Plans, Rossend Jardí, M. Schaper, Jordi Espuñes, Neus Cardeñosa, Francisco Rodríguez‐Frías, Rafael Esteban, Antoni Plasència, L. Salleras

Ngā utauta rapu:

Ngā marau whai pānga